A wide variety of plant-derived compounds, including the polyphenolic flavonoids, is present in the human diet or is consumed for medicinal reasons. Epidemiological and animal studies tend to suggest a protective effect of flavonoids against cardiovascular diseases and some types of cancer. Although flavonoids have been studied for about 50 years, the cellular mechanisms involved in their biological activity are still largely unknown. Antioxidant properties of the flavonoids have been postulated as a mechanism for putative protective effect against cardiovascular disease. Nevertheless, these properties alone are not sufficient to explain the anti-carcinogenic potential of these polyphenols. The mechanisms by which the molecules interact with cells or are absorbed by them are very important for determining the intracellular concentration and distribution of the metabolites to internal organs. With the exception of the cells lining the gastrointestinal tract, all other cells in the body are only exposed to flavonoid metabolites and degradation products. No previous studies have addressed this aspect of cellular exposure, except for some methylated metabolites. Within the last decade, reports on flavonoid activities have been largely associated with enzyme inhibition and anti-proliferative activity. From our recent work on the human colon cancer cell line HT29 and comparison with published studies, structure-function relationships demonstrate that antioxidant, enzyme inhibitor or anti-proliferative activities are dependent on particular structure motifs. The present review also presents a summary of mechanistic data on a few selected compounds.
Flavonoids: Structure-activity relationship: Enzyme inhibitor activities: Anti-proliferative activities: Antioxidant activities
Flavonoids are polycyclic structures containing two aromatic rings (A and B) linked by a heterocyclic ring C. Their consumption in the diet can vary (depending on dietary choice and availability of foods) between 20 mg/d and 1 g/d (Kuhnau, 1976; Hollman & Katan, 1999) . Geographical variation also accounts for wide differences in the type of flavonoids ingested, from isoflavonoid-rich food (e.g. soyabean) in Asia, to catechin derivatives (e.g. tea) in the UK. The study of flavonoid biochemistry began in the early 1950s, and by the beginning of the next decade, much of the chemistry of flavonoids (identification and determination of the mechanisms of synthesis and degradation in plants) was known. However, the analytical techniques and knowledge available at that time did not allow the study of the metabolism and cellular effects in more detail. Thousands of different flavonoids have been identified over the years, and new ones are still being isolated. For practical reasons we decided to concentrate on a defined range of subfamilies, with emphasis on the substitution pattern.
Flavonoids and health effects
Some flavonoids were originally considered procarcinogenic, partially because the catechol moiety in the B ring facilitated pro-oxidant reactions. However, Wattenberg (1985) was among the first researchers to suggest that flavonoids could have anti-mutagenic and anti-carcinogenic effects. A number of cohort epidemiological studies (Goldbohm et al. 1995; Hertog et al. 1995) (Hollman & Katan, 1999) . This finding led to the suggestion that flavonoids in general (but not flavonols only) have beneficial health effects. Increased amounts of data from in vitro and animal studies on flavonoids demonstrate the inhibition of initiation and development of tumours, but epidemiological evidence is still lacking (Hertog & Hollman, 1996) . Based on these in vitro and animal data, some flavonoids (flavopiridol, green-tea extracts and genistein conjugates) are undergoing clinical trials as anti-neoplastic drugs against gastrointestinal cancer, breast cancer and lymphomas respectively (Wang, 2000) . The effects on cardiovascular disease have been attributed to antioxidant properties. The antioxidant properties of flavonoids have been widely studied (for review, see Rice-Evans et al. 1996) . However, more recently, effects on enzyme inhibition (for example, see Alcaraz & Ferrandiz, 1987; Umarova et al. 1998; Mutoh et al. 2000a; Shimizu et al. 2000) and anti-proliferative activity (for example, see Agullo et al. 1996; Kamei et al. 1996; Kawaii et al. 1999; Kuntz et al. 1999) , including induction of the apoptotic pathways in tumour cells, have been observed. There is now clear evidence from animal models that a flavonoid-rich diet can protect against a range of carcinogenic insults. Caltagirone et al. (2000) showed that flavonoids can inhibit different phases of tumour formation in a mice melanoma model. Flavonoids in the diet at the same time as injection of the tumour cells delayed tumour growth. In addition, quercetin and apigenin, but not epigallocatechin gallate, can prevent metastasis. Conney et al. (1997) reviewed experiments in which curcumin could reduce the appearance of chemically-induced tumours of the skin (after topical application) and the gastrointestinal tract (after oral dose). The same effect was observed on chemically-induced colon cancer (Deschner et al. 1993) following a quercetin and rutin-containing diet. Mahmoud et al. (2000) showed that curcumin also prevent geneticallyinduced spontaneous tumour formation. Hayashi et al. (2000) finally demonstrated that quercetin chalcones can reduce tumour size in an implanted colon tumour in mice, i.e. it can affect tumour development rather than the initiation stage.
Flavonoids and carcinogenesis
It is now important to understand the mechanism by which a normal tissue can evolve into a neoplastic tumour. The carcinogenesis process is multi-stage and can span 10-20 years or more. There are three main stages. During the first or initiation stage a potential carcinogen is transformed into a mutagen product. Phase I metabolising enzymes (including cytochrome P450) catalyse the addition of a polar reactive group to a lipophilic carcinogen or xenobiotic to form a potent electrophile. They can then react with cellular neutrophiles, including DNA. Phase I metabolites can be detoxified by conjugation by phase II enzymes. The metabolites formed (e.g. sulfate or glutathione conjugates) are water soluble and easily eliminated from the body. The second stage is called the promotion stage. It can be further divided into four categories: (1) the over-expression of prooxidant enzymes (e.g. cyclo-oxygenase (prostaglandinendoperoxide synthase), lipoxygenase) leading to generation of reactive oxygen species and progression towards accumulation of DNA mutations. This process is very important in colon carcinogenesis promotion where all tumours over express cyclooxygenase 2; (2) another route for carcinogenesis is via over-expression of ornithine decarboxylase. This enzyme is involved in polyamine production, and is the limiting enzyme in nucleotide synthesis. The consequences of increased ornithine decarboxylase levels are an increase in DNA synthesis and therefore increase in cell proliferation; (3) DNA synthesis can also be directly increased by over-expression or activation of DNA polymerase or topoisomerase II; (4) cell proliferation can finally be increased by expression of the enzymes involved in the tight regulation of this process. Most of the regulation pathways are through protein phosphorylation and dephosphorylation via kinases and phosphatases. They include protein kinases A and C, mitogen-activated protein kinases and cyclin-dependent kinases. The final stage of carcinogenesis is called tumour development. At this stage the mutations are fixed and cells are proliferating in an uncontrolled manner. It is this phase at which cancers are currently detected. Intervention at this stage is confined to tumour reduction, stasis or strategies to block angiogenesis (Galati et al. 2000) .
It is clear now that carcinogenesis is the result of an imbalance in the tissue homeostasis. In a stable mature tissue the rates of replication and cell death are balanced. However, in certain circumstances the sustained rate of cell replication exceeds the rate of apoptosis, resulting in hyperplasia. Hyperplasia in itself does not imply that tumour development is inevitable. Cell proliferation is regulated by checkpoints at the major stages of the cell cycle, ensuring that the DNA sequence is correct before duplication, and that duplication and formation of the two chromatids is correct before the cell divides into two identical daughter cells. If any one of these checkpoints is overruled, the cell is prone to natural or induced (e.g. radiation or chemicals) mutations and unable to repair the damaged DNA. In mutated stem cells which escape apoptotic control, cells can become the progeny for a neoplastic cell population. This fragile balance between mitosis and apoptosis pathways is crucial.
To prevent tumour development, different stages of carcinogenesis can be targeted. To counteract the process of initiation, strategies include increasing phase II enzymes for rapid removal of the carcinogen, or redox reactions to reduce DNA damage. To regress the promotion stage there is need for enzyme inhibitors targeting ornithine decarboxylase or the different kinases involved in DNA Postgraduate Symposium synthesis. Reactive oxygen species formation can be prevented by enzyme inhibition or neutralised by the antioxidant activity of other molecules. Intervention in carcinogenesis at this early stage is clearly a preventive mechanism. Following diagnosis of cancers, the tumour is already developing, and changing the cell survival or proliferation routes is the only strategy for regression or stabilisation. There are three approaches to this strategy. First, and seemingly the easiest, is the induction of apoptosis of damaged cells, thus killing and regressing the tumour. Different strategies, depending on the product chosen and its mechanism of action, can be applied: (1) inhibition of topoisomerase would lead to random DNA strand breaks and eventually cell death. Such cell death is generally associated with arrest of the cell cycle in G2/M; (2) another strategy would be to disrupt mitochondrial membrane potential, releasing cytochrome c and procaspases, leading to a typical form of apoptosis detectable by DNA laddering. The same treatment would also lead to cytotoxicity if the respiratory chain is disrupted, ATP stocks depleted and reactive oxygen species formed, leading to cell death by oxidative stress. Thus, a fine control of this pathway is required as necrosis of the cell is not a possible option for the organism as a whole; (3) the final strategy would be by direct targeting of regulatory proteins, up regulating Bax or p21 or down regulating Bcl2 or p53 for induction of apoptosis (Galati et al. 2000) . The second tool to prevent carcinogenesis is to slow the cell cycle, allowing for DNA repair, but this approach would only be possible at the very early stages, where the mutation level is low and a correct copy of the DNA is still available. Finally, the third possibility is to arrest the cell cycle. Tumour cells cannot then divide, but are still prone to further mutation that may escape the regulation. However, this strategy is potentially important in the context of colonocytes, where the mitotic region is located at the base of the crypt. When cells exit this compartment, they migrate up the crypt to be exfoliated at the intestinal surface. Thus, damaged cells could be eliminated by apoptotic exfoliation. Any of these strategies would lead to tumour regression.
Bioavailability of flavonoids
As stated previously, there appears to be a large discrepancy between the potential effects, as observed in vitro, and observed effects in human subjects. This difference could be due to the poor bioavailability of flavonoids to target tissues in vivo, a process that is only just beginning to be understood. To have an effect on gastrointestinal cells, or any other tissue, these molecules need to either interact with the cell membrane or be absorbed. Flavonoids are present in the diet mainly as glycosides, and the nature of the sugar and position of substitution are important factors for intestinal absorption. Aglycones are thought to be freely available by passive diffusion in the small intestine, and plasma levels peak within 2 h after ingestion. Glycosides can undergo hydrolysis by colonic bacteria, releasing the aglycone for subsequent absorption.
However, many dietary flavonoid glucosides are absorbed at the small intestine (Walle et al. 2000) , as opposed to large intestine absorption (plasma peak at 1-2 h rather than 6-9 h after the meal). The current opinion is that flavonoid glucosides can be hydrolysed at the brush border by the enzyme lactate-phlorizin hydrolase Walle et al. 2000; . There is also additional indication for interaction with the neighbouring Na-dependent glucose transporter (SGLT1); (Gee et al. 1998 (Gee et al. , 2000 Choudhury et al. 1999; Walgren et al. 2000) followed by intracellular hydrolysis by β-glucosidase (Day et al. 1998) . Glycosides can also be hydrolysed by the colonic microflora; the resulting aglycones and smaller degradation products are absorbed by passive diffusion. There is also recent indication (Pforte et al. 1999 ) of stomach absorption. This mechanism is unclear, as the cellular and lumen contents show the same flavonoid profile (with lower concentrations in the cells), including glycosides. It is important to note also that there is still no evidence for acid-hydrolysis in the stomach. Once inside the intestinal or colonic cells, various transformations occur very rapidly, including deglucosylation, methylation, sulfation or glucuronidation. Conjugation can also take place in the liver as part of detoxification mechanisms. The efficiency of this process is such that very little of the flavonoid recovered in plasma or urine is present as the aglycone (Walle et al. 2000) . In addition, conjugated flavonoids (glucuronides and to a lesser extent sulfates) produced in the small intestine are rapidly excreted back to the intestinal lumen via the xenobiotic transporter MRP2 (Walle et al. 2000; Walgren et al. 2000) . When the glucuronide conjugates reach the colon, they may be hydrolysed by microbial enzymes and reabsorbed for a further enterohepatic cycling . Walle et al. (2001) showed that when volunteers were fed a meal containing the flavonoid chrysin, very small amounts of flavonoid conjugates were recovered in the plasma (mainly as sulfates), about 1000 times more in the urine (as glucuronides), but the major part of the dose was recovered unchanged from the faeces, showing a very low oral bioavailability. Except for the cells lining the gastrointestinal tract, all other cells in the body are only exposed to the flavonoid metabolites and degradation products, and plasma concentrations rarely exceed 1 µM (Hollman & Katan, 1999; Scalbert & Williamson, 2000) . There is, however, a possibility that some cells or tissues may accumulate flavonoid conjugates to higher, more biologically-active, concentrations due to high-affinity binding to receptors or cellular targets (Kuo, 1998; Spencer et al. 1999; Ader et al. 2000) . Finally, it is interesting to consider that the conjugation profile can vary slightly depending on the diet before the feeding experiment. Manach et al. (1997) showed that in rats adapted to a quercetin-rich food plasma concentration could reach 20 µM compared with 1 µM following a single dose exposure. This finding suggests a possible accumulation of quercetin in the plasma, perhaps due to albumin binding or a slow rate of excretion for some flavonoids.
Structure-function relationships
We have focused our studies on colonocytes, as they are one of the primary sites of exposure to flavonoids in the body, and because previous reports of the effect of flavonoids on these cells have been limited. In addition to the principle aglycones, we have included metabolites in our studies to assess systemic exposure, and natural or synthetic prenylated compounds for more information on substitution patterns. Screening was carried out using a cell viability assay in which neutral red dye is incorporated into lysosomes of live cells. The intensity of the dye is assessed by spectrophotometry and the data is proportional to the number of viable cells. Results are expressed as a percentage of the control sample (the same conditions as for the test compounds, but cells were exposed to solvent only). The threshold for an active compound is set to a statistically significant inhibition of cell growth, with a value < 90 % cell population compared with the control (also referred to as percentage survival) and P < 0·01. The ninety-six-well plate format allows high throughput screening of a large number of structures, and in all sixty-nine were tested. Although the assay measures total viable cells, and can therefore suggest changes in apoptotic or mitotic rates, it cannot differentiate between the causative mechanisms. It does, however, indicate where further investigation is warranted.
Structure-function relationships, mainly related to the core flavonoid skeleton, have been postulated. Our findings are broadly in agreement with the limited number of previously published data available on colon cells (Cushman & Nagarathnam, 1991; Agullo et al. 1996; Kuntz et al. 1999) . We found that only flavonoids with a given core structure suppress viability in the ninety-six-well plate assay. This group of compounds includes all flavones and flavonols (also identified by Agullo et al. 1996 and Kawaii et al. 1999 ) with inter-structure variations, irrespective of hydroxylation pattern. The results for these compounds range from 46 % survival for quercetin to 82 % survival for kaempferol. Of the other subclasses of flavonoids tested, flavanones, anthocyanidins, chalcones and isoflavones are not effective (see structures in (Fig. 1) . These findings seem in disagreement with those of Kuntz et al. (1999) , who postulate that at least some flavonoids from each of the subclasses are anti-proliferative. However, the authors also indicated that the concentrations necessary for such activity could reach 200 µM, which is considerably greater than the concentrations we have tested. The results of Agullo et al. (1996) and ours, however, indicate a very crucial role of the heterogenous ring C, as any variation of its structure leads to reduced activity. Such changes included: (1) saturation or opening of the ring and loss of the planar structure in the case of flavanones and chalcones respectively; (2) loss of the carbonyl group as in anthocyanins; (3) position of attachment of the aromatic ring B as in isoflavones. In addition, flavonoid glycosides are generally ineffective, irrespective of the nature or position of the sugar substitution. This factor is not as crucial, as intestinal and regression of carcinogenesis, with a particular interest in colon cancer. As part of our daily diet, flavonoids may be important factors in this process. They have been shown to have potent antioxidant properties, which are important in the prevention of the early stages of carcinogenesis, i.e. preventing DNA mutations. In addition to these well-studied processes, flavonoids are also good anti-proliferative agents. This aspect of flavonoid protection may be due in part to a large range of enzyme inhibition (e.g. kinases, pro-oxidant enzymes), and also apoptosis and cell cycle regulation. In our studies we have tested sixty-nine flavonoid structures for anti-proliferative activity and correlated the results with previously published data. New data has also emerged on the role of human metabolites found in plasma. With the exception of the 7-sulfate, all other conjugates tested were inactive against the human colon cancer cell line HT29. This finding suggests a luminal rather than systemic antiproliferative effect of flavonoids in the colon. These results also put into perspective experimental designs in which flavonoid glycosides and aglycones are tested on cell lines derived from other tissues, because these cell lines are unlikely to be exposed to such forms of the flavonoid. A subset of seventeen flavonoids is currently being investigated to identify in more detail the mechanisms involved in cellular anti-proliferation.
